{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:14Z","timestamp":1790805554200,"version":"4.1.0"},"reference-count":28,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Shandong Provincial Medical and Health Science and Technology Project","award":["202513050771"],"award-info":[{"award-number":["202513050771"]}]},{"name":"Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform","award":["GZY-KJS-SD-2023-051"],"award-info":[{"award-number":["GZY-KJS-SD-2023-051"]}]},{"name":"the Youth Innovation Team Development Program for Higher Education Institutions in Shandong Province","award":["2025KJJ028"],"award-info":[{"award-number":["2025KJJ028"]}]},{"name":"Yantai Municipal University-Local Integration and Development Program","award":["2023XDRHXMXK07"],"award-info":[{"award-number":["2023XDRHXMXK07"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2681363","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:11:06Z","timestamp":1790802666000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer"],"prefix":"10.1080","volume":"41","author":[{"given":"Chao","family":"Lin","sequence":"first","affiliation":[{"name":"Department Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Yantai Key Laboratory of Nanomedicine and Advanced Preparations, Yantai Institute of Materia Medica","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huateng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyan","family":"Wei","sequence":"additional","affiliation":[{"name":"Shandong Luye Pharmaceutical Co. Ltd","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"Department Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","first-page":"105659","DOI":"10.1016\/j.bioorg.2022.105659","article-title":"Facile synthesis of C1-substituted \u03b2-carbolines as CDK4 inhibitors for the treatment of cancer","volume":"121","author":"Li D","year":"2022","unstructured":"Li D, Liu W, Huang Y, Liu M, Tian C, Lu H, Jia H, Xu Z, Ding H, Zhao Q, et al. Facile synthesis of C1-substituted \u03b2-carbolines as CDK4 inhibitors for the treatment of cancer. Bioorg Chem. 2022;121:105659.","journal-title":"Bioorg Chem"},{"issue":"9","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy","volume":"65","author":"Shi Z","year":"2022","unstructured":"Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, Liu C, Liang C. From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J Med Chem. 2022;65(9):6390\u20136418.","journal-title":"J Med Chem"},{"issue":"7","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna S","year":"2009","unstructured":"Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547\u2013566.","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 Inhibitors","volume":"21","author":"Piezzo M","year":"2020","unstructured":"Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M, et al. Targeting cell cycle in breast cancer: CDK4\/6 Inhibitors. Int J Mol Sci. 2020;21(18):6479.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2018.10.001","article-title":"Targeting CDK4\/6 pathways and beyond in breast cancer","volume":"43","author":"Ribnikar D","year":"2019","unstructured":"Ribnikar D, Volovat SR, Cardoso F. Targeting CDK4\/6 pathways and beyond in breast cancer. Breast. 2019;43:8\u201317.","journal-title":"Breast"},{"issue":"17","key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41388-025-03378-0","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment","volume":"44","author":"Guo Z","year":"2025","unstructured":"Guo Z, Dong RW, Wu Y, Dong S, Alahari SK. Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment. Oncogene. 2025;44(17):1135\u20131152.","journal-title":"Oncogene"},{"issue":"3","key":"e_1_3_3_8_1","first-page":"286","article-title":"Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment","volume":"23","author":"Chen W","year":"2025","unstructured":"Chen W, Zhuang X, Chen Y, Yang H, Shen L, Feng S, Min W, Yuan K, Yang P. Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment. Chin J Nat Med. 2025;23(3):286\u2013298.","journal-title":"Chin J Nat Med"},{"issue":"2","key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-024-02144-y","article-title":"Efficacy and safety of CDK4\/6 inhibitors: a focus on HR+\/HER2-early breast cancer","volume":"85","author":"Klocker EV","year":"2025","unstructured":"Klocker EV, Egle D, Bartsch R, Rinnerthaler G, Gnant M. Efficacy and safety of CDK4\/6 inhibitors: a focus on HR+\/HER2-early breast cancer. Drugs. 2025;85(2):149\u2013169.","journal-title":"Drugs"},{"issue":"6577","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl A","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375(6577):eabc1495.","journal-title":"Science"},{"issue":"6","key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/phar.1756","article-title":"Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future","volume":"36","author":"DiPippo AJ","year":"2016","unstructured":"DiPippo AJ, Patel NK, Barnett CM. Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy. 2016;36(6):652\u2013667.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.tcb.2023.10.007","article-title":"Cancer takes many paths through G1\/S","volume":"34","author":"Knudsen ES","year":"2024","unstructured":"Knudsen ES, Witkiewicz AK, Rubin SM. Cancer takes many paths through G1\/S. Trends Cell Biol. 2024;34(8):636\u2013645.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn RS","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"18","key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi GN","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andr\u00e9 F, Winer EP, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u20131748.","journal-title":"N Engl J Med"},{"issue":"32","key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz MP","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tr\u00e9dan O, Chen S-C, Manso L, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u20133646.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal CL","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317\u2013331.","journal-title":"Drugs"},{"issue":"9","key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/jcph.902","article-title":"Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic\u2013pharmacodynamic modeling and simulation approach","volume":"57","author":"Sun W","year":"2017","unstructured":"Sun W, O\u2019Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D. Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic\u2013pharmacodynamic modeling and simulation approach. J Clin Pharmacol. 2017;57(9):1159\u20131173.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3389\/fonc.2019.00666","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice","volume":"9","author":"McCartney A","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, Galardi F, Risi E, De Santo I, Benelli M, et al. Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol. 2019;9:666.","journal-title":"Front Oncol"},{"issue":"1","key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher R","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan A-S, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Z\u00f6chbauer-M\u00fcller S, Zuber J, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125(1):90\u2013101.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla JJ","year":"2025","unstructured":"Asciolla JJ, Wu X, Adamopoulos C, Gavathiotis E, Poulikakos PI. Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer. Nat Cancer. 2025;6(1):24\u201340.","journal-title":"Nat Cancer"},{"issue":"3","key":"e_1_3_3_21_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","article-title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety","volume":"43","author":"Palmer CL","year":"2025","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, Huser N, Yuan JT, Cianfrogna JA, Sung T, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464\u2013481.e14.","journal-title":"Cancer Cell"},{"issue":"3","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccell.2025.02.007","article-title":"A CDK4-selective inhibitor puts the brakes on cancer cells","volume":"43","author":"Lin CC","year":"2025","unstructured":"Lin CC, Hanker AB. A CDK4-selective inhibitor puts the brakes on cancer cells. Cancer Cell. 2025;43(3):335\u2013337.","journal-title":"Cancer Cell"},{"issue":"16","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2023.41.16_suppl.3009","article-title":"First-in-human first-in-class phase 1\/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4\/6 inhibitors and endocrine therapy","volume":"41","author":"Yap TA","year":"2023","unstructured":"Yap TA, Giordano A, Hamilton EP, LoRusso P, Bowers M, Basu C, Billotte S, Delioukina M, Liu F, Yang J, et al. First-in-human first-in-class phase 1\/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4\/6 inhibitors and endocrine therapy. JCO. 2023;41(16_suppl):3009\u20133009.","journal-title":"JCO"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"104527","DOI":"10.1016\/j.breast.2025.104527","article-title":"BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+\/HER2-advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study","volume":"83","author":"Hu Z-Y","year":"2025","unstructured":"Hu Z-Y, Jiang K, Tian C, Zhang F, Shi Y, Wang Y, Li W, Wu B, Ding B, Liu L, et al. BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+\/HER2-advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study. Breast. 2025;83:104527.","journal-title":"Breast"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"26085","DOI":"10.1021\/acs.jmedchem.5c02137","article-title":"Discovery of atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor","volume":"68","author":"Gary MG","year":"2025","unstructured":"Gary MG, Cynthia P, Suvi O, et al. Discovery of atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor. J Med Chem. 2025;68:26085\u201326098.","journal-title":"J Med Chem"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"104663","DOI":"10.1016\/j.drudis.2026.104663","article-title":"Addressing delivery and resistance issues of CDK4\/6 inhibitors as cancer therapeutics","volume":"31","author":"Kshitiz L","year":"2026","unstructured":"Kshitiz L, Nalla UK, Sri PDC, et al. Addressing delivery and resistance issues of CDK4\/6 inhibitors as cancer therapeutics. Drug Discov Tod. 2026;31:104663.","journal-title":"Drug Discov Tod"},{"issue":"10","key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations: a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn R","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations: a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573\u2013583.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary B","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andr\u00e9 F, Loibl S, Loi S, Garcia-Murillas I, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u20131403.","journal-title":"Cancer Discov"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/cncr.32931","article-title":"Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: resistance mechanisms and novel treatment strategies","volume":"126","author":"Marina NS","year":"2020","unstructured":"Marina NS, Apoorva A, Patrick G, et al. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: resistance mechanisms and novel treatment strategies. Cancer. 2020;126:3400\u20133416.","journal-title":"Cancer"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2681363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2681363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2681363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:11:09Z","timestamp":1790802669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2681363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2681363"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2681363","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2681363"}}